Open AccessBioenergetic modulators hamper cancer cell viability and enhance response to chemotherapy
Author(s) -
TavaresValente Diana,
Granja Sara,
Baltazar Fátima,
Queirós Odília
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13642
Subject(s) - bioenergetics , viability assay , chemotherapy , cancer , cancer research , cancer cell , biology , chemistry , cell , medicine , microbiology and biotechnology , mitochondrion , biochemistry
Gliomas are characterized by a marked glycolytic metabolism with a consequent production of massive amounts of lactate, even in the presence of normal levels of oxygen, associated to increased invasion capacity and to higher resistance to conventional treatment. This work aimed to understand how the metabolic modulation can influence tumour aggressive features and its potential to be used as complementary therapy. We assessed the effect of bioenergetic modulators ( BM s) targeting different metabolic pathways in glioma cell characteristics. The in vivo effect of BM s was evaluated using the chicken chorioallantoic membrane model. Additionally, the effect of pre‐treatment with BM s in the response to the antitumour drug temozolomide ( TMZ ) was analysed in vitro. Cell treatment with the BM s induced a decrease in cell viability and in migratory/invasion abilities, as well as modifications in metabolic parameters (glucose, lactate and ATP ) and increased the cytotoxicity of the conventional drug TMZ . Furthermore, all BM s decreased the tumour growth and the number of blood vessels in an in vivo model. Our results demonstrate that metabolic modulation has the potential to be used as therapy to decrease the aggressiveness of the tumours or to be combined with conventional drugs used in glioma treatment.